SOUTH SAN FRANCISCO, CALIF., March 23, 2021 – Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced that Atul Dandekar, a successful business leader with nearly 25 years of pharmaceutical industry experience, has joined the Company…

Lead Programs Advancing for the Treatment of Pompe Disease, Chronic Kidney Disease and Amyotrophic Lateral Sclerosis Maze’s COMPASS Platform Unlocked Deep Genetic Insights, Combining Human Genetic Data, Functional Genomics and Data Science to Identify Lead Candidates Additional Novel Research Programs…

Maze Therapeutics has partnered to create two startups focused on cardiovascular and ophthalmic diseases. The startups will benefit from Maze’s human genetics and functional genomics platform as well as the capabilities of either Alloy Therapeutics or BridgeBio Pharma. Last year,…

The start­up has be­come the starter. Just un­der two years af­ter burst­ing on­to the scene with close to $200 mil­lion, Maze Ther­a­peu­tics is spin­ning out two new com­pa­nies, fo­cus­ing its hu­man ge­net­ics and func­tion­al ge­nomics plat­form on oph­thal­mol­o­gy and car­dio­vas­cu­lar…

  BioSpace is proud to present its NextGen Bio “Class of 2020,” a list of up-and-coming life sciences companies in North America that launched* no earlier than mid-2018. To come up with this list, BioSpace sorted companies into that age grouping, and…